Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
作者： Francis J Giles , Gianantonio Rosti , Photis Beris , Richard E Clark , Philipp le Coutre
DOI: 10.1586/EHM.10.61
关键词: Nilotinib 、 Surrogate endpoint 、 Internal medicine 、 Blastic Phase 、 Imatinib 、 Imatinib mesylate 、 Myelogenous 、 Medicine 、 Oncology 、 Myeloid leukemia 、 Leukemia 、 Pharmacology
摘要: Nilotinib (Tasigna(®)) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinib's deficiencies. has significant efficacy in patients with chronic myeloid leukemia (CML) phase, accelerated phase blastic following failure. Based on the results of Evaluating Efficacy Safety Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, US FDA granted approval nilotinib for treatment adult newly diagnosed Philadelphia chromosome-positive CML phase. Imatinib changed our perceptions therapeutic power targeted inhibition pathologically active kinase. Nilotinib, designer agent built scaffold, proven superior its template by every surrogate marker we use monitoring CML. Nilotinib's clinical superiority over imatinib, as demonstrated ENESTnd established it an that believe further step towards cure
expert-reviews.com参考文章(21)
F J Giles, M O'Dwyer, R Swords, Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia. ,vol. 23, pp. 1698- 1707 ,(2009) , 10.1038/LEU.2009.111
Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Gabriele Gugliotta, Adele Capucci, Michele Cedrone, Carmen Fava, Tamara Intermesoli, Giovanna Rege Cambrin, Fabio Stagno, Mario Tiribelli, Marilina Amabile, Simona Luatti, Angela Poerio, Simona Soverini, Nicoletta Testoni, Giovanni Martinelli, Giuliana Alimena, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, , Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia Blood. ,vol. 114, pp. 4933- 4938 ,(2009) , 10.1182/BLOOD-2009-07-232595
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis Giles, Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Design Development and Therapy. ,vol. 3, pp. 89- 101 ,(2009) , 10.2147/DDDT.S3069
F J Giles, E Abruzzese, G Rosti, D-W Kim, R Bhatia, A Bosly, S Goldberg, G L S Kam, M Jagasia, W Mendrek, T Fischer, T Facon, U Dünzinger, D Marin, M C Mueller, Y Shou, N J Gallagher, R A Larson, F-X Mahon, M Baccarani, J Cortes, H M Kantarjian, Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy Leukemia. ,vol. 24, pp. 1299- 1301 ,(2010) , 10.1038/LEU.2010.110
J B Singer, Y Shou, F Giles, H M Kantarjian, Y Hsu, A S Robeva, P Rae, A Weitzman, J M Meyer, M Dugan, O G Ottmann, UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. ,vol. 21, pp. 2311- 2315 ,(2007) , 10.1038/SJ.LEU.2404827
Hagop Kantarjian, Francis Giles, Lydia Wunderle, Kapil Bhalla, Susan O'Brien, Barbara Wassmann, Chiaki Tanaka, Paul Manley, Patricia Rae, William Mietlowski, Kathy Bochinski, Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jorge Cortes, Leila Alland, Oliver G. Ottmann, Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL The New England Journal of Medicine. ,vol. 354, pp. 2542- 2551 ,(2006) , 10.1056/NEJMOA055104
John M. Goldman, Chronic Myeloid Leukemia: Reversing the Chronic Phase Journal of Clinical Oncology. ,vol. 28, pp. 363- 365 ,(2010) , 10.1200/JCO.2009.26.5587
Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Francis J. Giles, Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors Targeted Oncology. ,vol. 4, pp. 99- 105 ,(2009) , 10.1007/S11523-009-0110-4
Ronan Swords, Yesid Alvarado, Jorge Cortes, Francis J. Giles, Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Current Hematologic Malignancy Reports. ,vol. 2, pp. 83- 88 ,(2007) , 10.1007/S11899-007-0012-4
Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Francis J. Giles, Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: Comparative safety profiles of newer agents Leukemia & Lymphoma. ,vol. 51, pp. 1399- 1413 ,(2010) , 10.3109/10428194.2010.491135